Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
about
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosisN-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.Anthraquinone-2-sulfonic acid (AQ2S) is a novel neurotherapeutic agentA mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone.Managing MS in a changing treatment landscape.A critical appraisal of treatment decisions in multiple sclerosis--old versus new.Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.The current role of mitoxantrone in the treatment of multiple sclerosis.Anthraquinones As Pharmacological Tools and Drugs.A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1-AMPK-mTOR signaling pathway.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Therapeutic concentrations of mitoxantrone elicit energetic imbalance in H9c2 cells as an earlier event.Frequency of Blood-tissue Parasitic Infections in Patients with Multiple Sclerosis, as Compared to their Family Members.Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice.Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica.Impaired Cardiac Function in Patients with Multiple Sclerosis by Comparison with Normal Subjects.Multiple sclerosis broke my heart.Mitochondrial Cumulative Damage Induced by Mitoxantrone: Late Onset Cardiac Energetic Impairment
P2860
Q34922742-F204AA36-4E85-4E6E-8080-2B77D5969451Q35756367-6BDB2B33-61A9-4124-9F6D-EC7BB3706CBAQ36062456-C8E13B04-D293-480E-A472-91362401E33BQ36586480-A744DC66-BD82-4455-9492-FB43578BF256Q36960355-93B0D555-2DA5-48F3-8014-41A6B5555E81Q37200093-1C5C1469-60CF-4CA5-873D-F71F24A62CA1Q37857752-A019C4F2-BE53-443C-B973-74026959AED1Q37862062-7E54AC77-904A-4762-8FF8-CD3146790482Q38150405-3C87010C-FDDB-41B9-BAD9-8CAE43F10F31Q38164425-EB9A1347-36A5-4C14-8E40-CD4B54EC1600Q38172961-9A5672E4-5F5B-480D-AD35-36678460C59DQ38212259-24435311-069B-4EDE-95C0-C4455A1D7805Q38816745-19A533A5-0D89-41FF-81FE-BA849A60B4F0Q38977013-C9A1755E-E85B-42BC-9774-11BE3CC17E8EQ39021942-C1ECD12A-C246-4241-854F-B2559A1BDD44Q39094453-370D2C4C-3CCC-4F48-B577-847F81DCF622Q41467477-F8763B0D-27CB-40A2-9A92-683D116F0A27Q41998267-2742E45F-771C-4400-9024-51669F196AD8Q47694093-4E434CB4-4570-448C-86EA-C30EEFCF8F83Q47926002-819942EB-D631-4EE9-B44B-13B1677805AFQ49829881-E1C11B3F-7B27-4B37-8693-BD4389257E55Q52097587-1B99AE1E-7AF6-487C-8F07-14B4DBCBC508Q58229934-E33C49A2-3BF9-4B72-A8B2-7CA35CA08C7C
P2860
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
@ast
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
@en
type
label
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
@ast
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
@en
prefLabel
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
@ast
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
@en
P2093
P2860
P50
P1433
P1476
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS
@en
P2093
P2860
P304
P356
10.1212/WNL.0B013E3181E0F7E6
P407
P577
2010-04-28T00:00:00Z